World Journal of Endocrine Surgery

Register      Login

VOLUME 11 , ISSUE 1 ( January–April, 2019 ) > List of Articles


Association of Biochemical and Histological Features with Parafibromin, Galectin-3, and PGP9.5 in Parathyroid Neoplasms

Niraj Kumari, Nandita Chaudhary, Narendra Krishnani

Keywords : Galectin-3, Hypercalcemic crisis, Oncocytic, Parafibromin, Parathyroid carcinoma, PGP9.5

Citation Information : Kumari N, Chaudhary N, Krishnani N. Association of Biochemical and Histological Features with Parafibromin, Galectin-3, and PGP9.5 in Parathyroid Neoplasms. World J Endoc Surg 2019; 11 (1):6-14.

DOI: 10.5005/jp-journals-10002-1246

License: CC BY-NC 4.0

Published Online: 01-04-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Background: Carcinoma in parathyroid is diagnosed when there is recurrence or metastasis or fulfillment of histological criteria. Immunohistochemical (IHC) markers are used to assist in difficult cases. Associations of IHC markers with unfavorable clinical or histological features that predict aggressive behavior of parathyroid neoplasms have not been reported so far. We planned to study the direct association of IHC markers with biochemical and histological features in parathyroid neoplasms. Materials and methods: IHC for parafibromin (PF), adenosis polyposis coli (APC), galectin-3 (Gal-3), and PGP9.5 was performed and correlated with biochemical and histological features. Result: PF loss, Gal-3, and PGP9.5 overexpression alone or in combination showed significant association with one or more features like hypercalcemic crisis; low serum vitamin D; raised serum alkaline phosphatase (ALP); diffuse sheet pattern; predominant oncocytic histology; diffuse macronucleoli; thick fibrous bands; and capsular, vascular, and adjacent tissue invasion. The majority of histological features that significantly correlated with the expression or loss of IHC makers is included in the current criteria for diagnosing malignancy in parathyroid neoplasms. Conclusion: The presence of hypercalcemic crisis and predominant oncocytic histology showed significant association with IHC markers related to parathyroid malignancy. Inclusion of these features in current criteria may make it more comprehensive for predicting malignancy in parathyroid neoplasms, though the search for reliable factors predicting malignancy still continues.

  1. DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol 2011;24:S78–S93. DOI: 10.1038/modpathol.2010.132.
  2. Shane E. Clinical review 122. Parathyroid carcinoma. J Clin Endocrinol Metab 2001;86:485–493. DOI: 10.1210/jcem.86.2.7207.
  3. Harinarayan CV, Gupta N, et al. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol 1995;43:351–358.
  4. Agarwal G, Prasad KK, et al. Indian primary hyperpara-thyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology. World J Surg 2006;30:732–742. DOI: 10.1007/s00268-005-0366-5.
  5. Soin AS, Gupta S, et al. Primary hyperparathyroidism- an Indian study. Indian J Cancer 1994;31:72–77.
  6. Diaconescu MR, Glod M, et al. Clinicopathological phenotype of parathyroid carcinoma: therapeutic and prognostic aftermaths. Chirurgia 2015;110:66–71.
  7. Chan JKC. Tumors of thyroid and parathyroid glands. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 4th ed. China: Elsevier Saunders, 2013; pp.1273–1293, vol. 2.
  8. Chan JK, Tsang WY. Endocrine malignancies that may mimic benign lesions. Semin Diagn Pathol 1995;12:45–63.
  9. Bondeson L, Grimelius L, et al. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, ed. World Health Organization Classification of Tumors, Pathology & Genetics Tumors of Endocrine Organs. Lyon: IARC Press, 2004; pp.124–127.
  10. Sandelin K, Tullgren O, et al. Clinical course of metastatic parathyroid cancer. World J Surg 1994;18:594–598.
  11. Marsh DJ, Hahn MA, et al. Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opin Med Diagn 2007;1:377–392. DOI: 10.1517/17530059.1.3.377.
  12. Howell VM, Gill A, et al. Accuracy of combined gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009;94:434–441. DOI: 10.1210/jc.2008-1740.
  13. Kim HK, Oh YL, et al. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck 2012;34:201–206.
  14. Erickson LA, Jin L, et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 1999;23:288–295.
  15. Farnebo F, Auer G, et al. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 1999;23:68–74.
  16. Vargas MP, Vargas HI, et al. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 1997;10:12–17.
  17. Vasef MA, Brynes RK, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999;12:412–416.
  18. Juhlin CC, Hooq A. Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse? Int J Endocrinol 2010;324964. DOI: 10.1155/2010/324964.
  19. Wang O, Wang CY, et al. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J 2012;125:2895–2901.
  20. Lin L, Zhang JH, et al. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci U S A 2008;105:17420–17425. DOI: 10.1073/ pnas.0710725105.
  21. Cui C, Lal P, et al. Expression of parafibromin in major renal cell tumors. Eur J Histochem 2012;56:e39. DOI: 10.4081/ejh.2012.e39.
  22. Fernandez-Ranvier GG, Khanafshar E, et al. Defining a Molecular Phenotype for Benign and Malignant Parathyroid tumors. Cancer 2009;115:334–344. DOI: 10.1002/cncr.24037.
  23. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004;9:305–328.
  24. Song L, Tang JW, et al. Galectin-3 in cancer. Clin Chim Acta 2014;431: 185–191. DOI: 10.1016/j.cca.2014.01.019.
  25. Tokumaru Y, Yamashita K, et al. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 2008;123:753–759. DOI: 10.1002/ijc.23354.
  26. Tezel E, Hibi K, et al. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000;6:4764–4767.
  27. Yamazaki T, Hibi K, et al. PGP 9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002;8:192–195.
  28. Hibi K, Westra WH, et al. PGP9.5 As a Candidate Tumor Marker for Non-Small-Cell Lung Cancer. Am J Pathol 1999;155:711–715. DOI: 10.1016/S0002-9440(10)65169-3.
  29. Campbell LK, Thomas JR, et al. Protein gene product (PGP 9.5) is not a specific marker of neural and nerve sheath tumors: an immunohistochemical study of 95 mesenchymal neoplasms. Mod Pathol 2003;16:963–969. DOI: 10.1097/01.MP.0000087088.88280.B0.
  30. Bergero N, De Pompa R, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908–914. DOI: 10.1016/j.humpath.2005.06.020.
  31. Saggiorato E, Bergero N, et al. Galectin-3 and Ki67 expression in multiglandular parathyroid lesions. Am J Clin Pathol 2006;126:59–66. DOI: 10.1309/9NXP-7FRF-87MU-2PCK.
  32. Tan MH, Morrison C, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004;10:6629–6637. DOI: 10.1158/1078-0432.CCR-04-0493.
  33. Gill AJ, Clarkson A, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidismjaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006;30:1140–1149. DOI: 10.1097/01.pas.0000209827.39477.4f.
  34. Juhlin CC, Villablanca A, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr-Relat Cancer 2007;14:501–512. DOI: 10.1677/ ERC-07-0021.
  35. Juhlin CC, Haglund F, et al. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 2009;34: 481–492.
  36. Juhlin CC, Nillson IL, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 2010;21:166–177. DOI: 10.1007/s12022-010-9121-z.
  37. Truran PP, Johnson SJ, et al. Parafibromin, Galectin-3, PGP9.5, Ki67, and Cyclin D1: Using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg 2014;38:2845–2854. DOI: 10.1007/s00268-014-2700-2.
  38. LiVolsi VA, Baloch Z, et al. Oncocytic lesions of the neuroendocrine system. Adv Anat Pathol 2014;21:69–82. DOI: 10.1097/ PAP.0000000000000011.
  39. Kumari N, Chaudhary N, et al. Role of histological criteria and immunohistochemical markers in predicting risk of malignancy in parathyroid neoplasms. Endocr Pathol 2016;27:87–96. DOI: 10.1007/ s12022-016-9426-7.
  40. Brown S, O'Neill C, et al. Parathyroid carcinoma: increasing incidence and changing presentation. ANZ J Surg 2011;81:528–532.
  41. Kruijff S, Sidhu SB, et al. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol 2014;2:426–433. DOI: 10.1245/s10434-013-3288-8.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.